Mink Therapeutics Inc
NASDAQ:INKT
Mink Therapeutics Inc
NASDAQ:INKT
Price:
9.63
USD
5.53%
Market Cap:
$45.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Mink Therapeutics Inc
NASDAQ:INKT
|
US |
|
Cellnex Telecom SA
MAD:CLNX
|
ES |
|
John Menzies PLC
LSE:MNZS
|
UK |
|
Marg Techno-Projects Ltd
BSE:540254
|
IN |
|
Definity Financial Corp
F:XR6
|
CA |
|
Duroc AB
STO:DURC B
|
SE |
|
Danto Holdings Corp
TSE:5337
|
JP |
|
A
|
Arion banki hf
ICEX:ARION
|
IS |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of INKT.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
INKT
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
INKT Competitors Multiples
Mink Therapeutics Inc Competitors
Mink Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Mink Therapeutics Inc
NASDAQ:INKT
|
44.3m USD | 0 | -3.6 | -2.9 | -2.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.2B USD | 6.1 | 89.4 | 14.8 | 20.6 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.4B USD | 6.2 | -96.2 | 951.3 | -107.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.9B USD | 5.7 | 19.8 | 12.4 | 15.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD | 9.3 | 28.2 | 21.1 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.5 | 17.4 | 12.9 | 14.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.6B AUD | 3.2 | 34.9 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
